Literature DB >> 31092591

Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964-2014.

Ola Olén1,2,3, Johan Askling1, Michael C Sachs1, Martin Neovius1, Karin E Smedby1, Anders Ekbom1, Jonas F Ludvigsson4,5,6,7.   

Abstract

OBJECTIVES: To examine all-cause and cause-specific mortality in adult-onset and elderly-onset IBD and to describe time trends in mortality over the past 50 years.
DESIGN: Swedish nationwide register-based cohort study 1964-2014, comparing mortality in 82 718 incident IBD cases (inpatient and non-primary outpatient care) with 10 times as many matched general population reference individuals (n=801 180) using multivariable Cox regression to estimate HRs. Among patients with IBD, the number of participants with elderly-onset (≥60 years) IBD was 17 873.
RESULTS: During 984 330 person-years of follow-up, 15 698/82 718 (19%) of all patients with IBD died (15.9/1000 person-years) compared with 121 095/801 180 (15.1%) of reference individuals, corresponding to an HR of 1.5 for IBD (95% CI=1.5 to 1.5 (HR=1.5; 95% CI=1.5 to 1.5 in elderly-onset IBD)) or one extra death each year per 263 patients. Mortality was increased specifically for UC (HR=1.4; 95% CI=1.4 to 1.5), Crohn's disease (HR=1.6; 95% CI=1.6 to 1.7) and IBD-unclasssified (HR=1.6; 95% CI=1.5 to 1.8). IBD was linked to increased rates of multiple causes of death, including cardiovascular disease (HR=1.3; 1.3 to 1.3), malignancy (HR=1.4; 1.4 to 1.5) and digestive disease (HR=5.2; 95% CI=4.9 to 5.5). Relative mortality during the first 5 years of follow-up decreased significantly over time. Incident cases of 2002-2014 had 2.3 years shorter mean estimated life span than matched comparators.
CONCLUSIONS: Adult-onset and elderly-onset patients with UC, Crohn's disease and IBD-unclassified were all at increased risk of death. The increased mortality remained also after the introduction of biological therapies but has decreased over time. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  Crohn’s disease; IBD; IBD unclassified; Indeterminate IBD; Ulcerative colitis; cause-specific; death; death cause; mortality; myocardial infarction

Year:  2019        PMID: 31092591     DOI: 10.1136/gutjnl-2018-317572

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  17 in total

1.  A Novel Method for Quantifying Intestinal Inflammatory Burden in Inflammatory Bowel Disease Using Register Data.

Authors:  Jordan E Axelrad; Michael C Sachs; Jonas F Ludvigsson; Ola Olén
Journal:  Clin Epidemiol       Date:  2020-10-09       Impact factor: 4.790

2.  Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review.

Authors:  Nghia H Nguyen; Ivonne Martinez; Ashish Atreja; Amy M Sitapati; William J Sandborn; Lucila Ohno-Machado; Siddharth Singh
Journal:  Am J Gastroenterol       Date:  2022-01-01       Impact factor: 10.864

3.  Altered Pattern of Immunoglobulin A-Targeted Microbiota in Inflammatory Bowel Disease After Fecal Transplantation.

Authors:  Wen-Qi Huang; Hong-Li Huang; Wu Peng; Yan-Di Liu; You-Lian Zhou; Hao-Ming Xu; Liang-Jie Zhang; Chong Zhao; Yu-Qiang Nie
Journal:  Front Microbiol       Date:  2022-06-22       Impact factor: 6.064

4.  Progression of Elderly Onset Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-Based Cohort Studies.

Authors:  Jacob J Rozich; Parambir S Dulai; Mathurin Fumery; William J Sandborn; Siddharth Singh
Journal:  Clin Gastroenterol Hepatol       Date:  2020-03-03       Impact factor: 11.382

Review 5.  Management of Inflammatory Bowel Diseases in Special Populations: Obese, Old, or Obstetric.

Authors:  Siddharth Singh; Sherman Picardo; Cynthia H Seow
Journal:  Clin Gastroenterol Hepatol       Date:  2019-11-08       Impact factor: 11.382

Review 6.  Positioning Therapies in the Management of Crohn's Disease.

Authors:  Nghia H Nguyen; Siddharth Singh; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2019-10-30       Impact factor: 11.382

7.  Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study.

Authors:  Vera E R Asscher; Vince B C Biemans; Marieke J Pierik; Gerard Dijkstra; Mark Löwenberg; Sander van der Marel; Nanne K H de Boer; Alexander G L Bodelier; Jeroen M Jansen; Rachel L West; Jeoffrey J L Haans; Willemijn A van Dop; Rinse K Weersma; Frank Hoentjen; P W Jeroen Maljaars
Journal:  Aliment Pharmacol Ther       Date:  2020-09-09       Impact factor: 8.171

8.  Inflammatory bowel disease and risk of severe COVID-19: A nationwide population-based cohort study in Sweden.

Authors:  Jonas F Ludvigsson; Jordan Axelrad; Jonas Halfvarson; Hamed Khalili; Emma Larsson; Paul Lochhead; Bjorn Roelstraete; Tracey G Simon; Jonas Söderling; Ola Olén
Journal:  United European Gastroenterol J       Date:  2021-03-11       Impact factor: 6.866

9.  Risks of developing ulcerative colitis and Crohn's disease in relation to silica dust exposure in Sweden: a case-control study.

Authors:  Albin Wallden; Pål Graff; Ing-Liss Bryngelsson; Louise Fornander; Pernilla Wiebert; Per Vihlborg
Journal:  BMJ Open       Date:  2020-02-16       Impact factor: 2.692

10.  Work Loss in Relation to Pharmacological and Surgical Treatment for Crohn's Disease: A Population-Based Cohort Study.

Authors:  Åsa H Everhov; Michael C Sachs; Jonas F Ludvigsson; Hamed Khalili; Johan Askling; Martin Neovius; Pär Myrelid; Jonas Halfvarson; Caroline Nordenvall; Jonas Söderling; Ola Olén
Journal:  Clin Epidemiol       Date:  2020-03-10       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.